Sources
Help build the largest human-edited directory on the web.
Submit a site - Become an editor
Wikipedia. Licensed under the GNU Free Documentation License.
Are you an expert in this subject? Join the discussion and share your knowledge at Wikipedia.org.
Small interfering RNA
From Wikipedia, the free encyclopedia
Small interfering RNA (siRNA), sometimes known as short interfering RNA or silencing RNA, are a class of 20-25 nucleotide-long double-stranded RNA molecules that play a variety of roles in biology. Most notably, siRNA is involved in the RNA interference (RNAi) pathway where the siRNA interferes with the expression of a specific gene. In addition to their role in the RNAi pathway, siRNAs also act in RNAi-related pathways, e.g. as an antiviral mechanism or in shaping the chromatin structure of a genome; the complexity of these pathways is only now being elucidated.
siRNAs were first discovered by David Baulcombe's group in Norwich, England, as part of post-transcriptional gene silencing (PTGS) in plants, and published their findings in Science in a paper titled "A species of small antisense RNA in posttranscriptional gene silencing in plants".[1] Shortly thereafter, in 2001, synthetic siRNAs were then shown to be able to induce RNAi in mammalian cells by Thomas Tuschl and colleagues in a paper published in Nature.[2] This discovery led to a surge in interest in harnessing RNAi for biomedical research and drug development.
Contents |
SiRNAs have a well defined structure: a short (usually 21-nt) double-strand of RNA (dsRNA) with 2-nt 3' overhangs on either end:
Each strand has a 5' phosphate group and a 3' hydroxyl (-OH) group. This structure is the result of processing by dicer, an enzyme that converts either long dsRNAs or small hairpin RNAs into siRNAs.[3] SiRNAs can also be exogenously (artificially) introduced into cells by various transfection methods to bring about the specific knockdown of a gene of interest. Essentially any gene of which the sequence is known can thus be targeted based on sequence complementarity with an appropriately tailored siRNA. This has made siRNAs an important tool for gene function and drug target validation studies in the post-genomic era.
Transfection of an exogenous siRNA can be problematic, since the gene knockdown effect is only transient, particularly in rapidly dividing cells. One way of overcoming this challenge is to modify the siRNA in such a way as to allow it to be expressed by an appropriate vector, e.g. a plasmid. This is done by the introduction of a loop between the two strands, thus producing a single transcript, which can be processed into a functional siRNA. Such transcription cassettes typically use an RNA polymerase III promoter (e.g. U6 or H1), which usually direct the transcription of small nuclear RNAs (snRNAs) (U6 is involved in gene splicing; H1 is the RNase component of human RNase P). It is assumed (although not known for certain) that the resulting siRNA transcript is then processed by Dicer.
RNAi intersects with a number of other pathways, so it is not surprising that on occasion non-specific effects are triggered by the experimental introduction of an siRNA. When a mammalian cell encounters a double-stranded RNA such as an siRNA, it may mistake it as a viral by-product and mount an immune response. Furthermore, since structurally related microRNAs modulate gene expression largely via incomplete complementarity with a target mRNA, unintended off-targeting may be effected by the introduction of an siRNA.
Introduction of too much siRNA can result in non-specific events due to activation of innate immune responses. Most papers suggest that this is probably due to activation of the dsRNA sensor PKR, although retinoic acid inducible Gene I (RIG-I) may also be involved. The induction of cytokines via Toll-like receptor 7 (TLR7) has also been described. One promising method of reducing the non-specific effects is to convert the siRNA into a microRNA. MicroRNAs occur naturally, and by harnessing this endogenous pathway it should be possible to achieve similar gene knockdown at comparatively low concentrations of resulting siRNAs. This should minimize non-specific effects.
Off-targeting is another challenge facing siRNAs as a gene knockdown tool. Here, genes with incomplete complementarity are inadvertently downregulated by the siRNA (effectively, the siRNA acts as an miRNA), leading to problems in data interpretation and potential toxicity. This however can be partly addressed by designing appropriate control experiments, and siRNA design algorithms are currently being developed to produce siRNAs free from off-targeting. Genome-wide expression analysis, e.g. by microarray technology, can then be used to verify this and further refine the algorithms. A 2006 paper from the laboratory of Dr Khvorova implicates 6 or 7 basepairs long stretches from position 2 onwards in the siRNA matching with 3'UTR regions in off-targeted genes.[4]
Given the ability to knockdown essentially any gene of interest, RNAi via siRNAs has generated a great deal of interest in both basic and applied biology. There is an increasing number of large-scale RNAi screens that are designed to identify the important genes in various biological pathways. As disease processes also depend on the activity of multiple genes, it is expected that in some situations turning off the activity of a gene with a siRNA could produce a therapeutic benefit.
However, applying RNAi via siRNAs to living animals, especially humans, poses many challenges. siRNAs show different effectiveness in different cell types in a manner yet poorly understood: some cells respond well to siRNAs and show a robust knockdown, others show no such knockdown (even despite efficient transfection).
Phase I results of the first two therapeutic RNAi trials (indicated for age-related macular degeneration, aka AMD) reported at the end of 2005, demonstrate that siRNAs are well tolerated and have suitable pharmacokinetic properties. siRNAs and related RNAi induction methods therefore stand to become an important new class of drugs in the foreseeable future.
Ian McEwan's novel "Saturday" suggests an siRNA-based treatment for Huntington's Disease.
MicroRNA (miRNA) are a related class of gene regulatory small RNAs, typically 21-23nt in length. They typically differ from siRNA because they are processed from single stranded RNA precursors and show only partial complementarity to mRNA targets. They have been implicated in a wide range of functions such as cell growth and apoptosis, development, neuronal plasticity and remodeling, and even insulin secretion. miRNAs have also been implicated in disease: e.g. an overabundance of miRNA has been reported in cases of Fragile X Mental Retardation, while some cancers are associated with up- and downregulation of certain miRNA genes.
Initial studies have indicated that miRNAs regulate gene expression post-transcriptionally at the level of translational inhibition at P-Bodies in the cytoplasm. However, miRNAs may also guide mRNA cleavage similar to siRNAs. This is often the case in plants where the target sites are typically highly complementary to the miRNA. While target sites in plant mRNAs can be found in the 5'UTR, open-reading frames and 3'UTR, in animals it is the 3' UTR that is the main target. This difference between plants and animals may be explained by their different modes of gene silencing.
miRNAs are first transcribed as part of a primary microRNA (pri-miRNA). This is then processed by the Drosha with the help of Pasha/DGCR8 (=Microprocessor complex) into pre-miRNAs. The ~75nt pre-miRNA is then exported to the cytoplasm by exportin-5, where it is then diced into 21-23nt siRNA-like molecules by Dicer. In some cases, multiple miRNAs can be found on the pri-miRNA.
Check out an illustrated tutorial on miRNA.[1]
- ^ Hamilton A, Baulcombe D (1999). "A species of small antisense RNA in posttranscriptional gene silencing in plants". Science 286 (5441): 950-2. PMID 10542148.
- ^ Elbashir S, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T (2001). "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells". Nature 411 (6836): 494-8. PMID 11373684.
- ^ Bernstein E, Caudy A, Hammond S, Hannon G (2001). "Role for a bidentate ribonuclease in the initiation step of RNA interference". Nature 409 (6818): 363-6. PMID 11201747.
- ^ Birmingham A, Anderson E, Reynolds A, Ilsley-Tyree D, Leake D, Fedorov Y, Baskerville S, Maksimova E, Robinson K, Karpilow J, Marshall W, Khvorova A (2006). "3' UTR seed matches, but not overall identity, are associated with RNAi off-targets". Nat Methods 3 (3): 199-204. PMID 16489337.
- Hannon G, Rossi J (2004). "Unlocking the potential of the human genome with RNA interference". Nature 431 (7006): 371-8. PMID 15372045.
- Fire A, Xu S, Montgomery M, Kostas S, Driver S, Mello C (1998). "Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans". Nature 391 (6669): 806-11. PMID 9486653. The original paper by Fire et. al. describing RNAi
- Elbashir S, Lendeckel W, Tuschl T (2001). "RNA interference is mediated by 21- and 22-nucleotide RNAs". Genes Dev 15 (2): 188-200. PMID 11157775.
- Zamore P, Tuschl T, Sharp P, Bartel D (2000). "RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals". Cell 101 (1): 25-33. PMID 10778853.
- Hamilton A, Baulcombe D (1999). "A species of small antisense RNA in posttranscriptional gene silencing in plants". Science 286 (5441): 950-2. PMID 10542148. First description of siRNAs.
- Zhang Z, Weinschenk T, Guo K, Schluesener H (2006). "siRNA binding proteins of microglial cells: PKR is an unanticipated ligand". J Cell Biochem 97 (6): 1217-29. PMID 16315288.
- Kim D, Behlke M, Rose S, Chang M, Choi S, Rossi J (2005). "Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy". Nat Biotechnol 23 (2): 222-6. PMID 15619617.
- Sledz C, Williams B (2004). "RNA interference and double-stranded-RNA-activated pathways". Biochem Soc Trans 32 (Pt 6): 952-6. PMID 15506933.
- Pebernard S, Iggo R (2004). "Determinants of interferon-stimulated gene induction by RNAi vectors". Differentiation 72 (2-3): 103-11. PMID 15066190.
- Sledz C, Holko M, de Veer M, Silverman R, Williams B (2003). "Activation of the interferon system by short-interfering RNAs". Nat Cell Biol 5 (9): 834-9. PMID 12942087.
Tools for design and quality:
- Deqor: A web-based tool for the design and quality control of siRNAs
- siDirect: a web-based online software system for designing siRNA sequences
- siSearch: a siRNA design tool using a number of popular design methods
- SpecificityServer: a tool for checking the specificity of a given siRNA
- miRacle: tool for prediction of siRNA and microRNA targets using an algorithm which incorporates RNA secondary structure
Databases:
| Major Families of Biochemicals | ||
| Peptides | Amino acids | Nucleic acids | Carbohydrates | Lipids | Terpenes | Carotenoids | Tetrapyrroles | Enzyme cofactors | Steroids | Flavonoids | Alkaloids | Polyketides | Glycosides | ||
| Analogues of nucleic acids: | Types of Nucleic Acids | Analogues of nucleic acids: |
| Nucleobases: | Adenine | Thymine | Uracil | Guanine | Cytosine | Purine | Pyrimidine | |
|---|---|---|
| Nucleosides: | Adenosine | Uridine | Guanosine | Cytidine | Deoxyadenosine | Thymidine | Deoxyguanosine | Deoxycytidine | |
| Nucleotides: | AMP | UMP | GMP | CMP | ADP | UDP | GDP | CDP | ATP | UTP | GTP | CTP | cAMP | cADPR | cGMP | |
| Deoxynucleotides: | dAMP | TMP | dGMP | dCMP | dADP | TDP | dGDP | dCDP | dATP | TTP | dGTP | dCTP | |
| Ribonucleic acids: | RNA | mRNA | piRNA | tRNA | rRNA | ncRNA | sgRNA | shRNA | siRNA | snRNA | miRNA | snoRNA | LNA | |
| Deoxyribonucleic acids: | DNA | mtDNA | cDNA | plasmid | Cosmid | BAC | YAC | HAC | |
| Analogues of nucleic acids: | GNA | PNA | TNA | morpholino | |